Ethnopharmacological relevance: The ethanolic extract of Lychnophora trichocarpha Spreng. is used in Brazilian folk medicine to treat bruise, pain and inflammatory diseases. Aim of the study: The present study aimed at investigating whether ethanolic extract of L. trichocarpha, its ethyl acetate fraction and its main bioactive compounds could be useful to treat gouty arthritis by countering hyperuricemia and inflammation. Materials and methods: L. trichocarpha ethanolic extract (LTE), ethyl acetate fraction from ethanolic extract (LTA) and isolated compounds were evaluated for urate-lowering activity and liver xanthine oxidase (XOD) inhibition in oxonate-induced hyperuricemic mice. Anti-inflammatory activity in monosodium urate crystal-induced paw oedema, an experimental model of gouty arthritis, was also investigated. Results: Crude ethanolic extract and its ethyl acetate fraction showed significant urate-lowering effects. LTE was also able to significantly inhibit liver xantine oxidase (XOD) activity in vivo at the dose of 250 mg/ kg. Luteolin, apigenin, lupeol, lychnopholide and eremantholide C showed the anti-hyperuricemic activities among tested compounds. Apigenin also showed XOD inhibitory activity in vivo. Luteolin, lychnopholide, lupeol and eremantholide C, in turn, did not shown significant inhibitory activity towards this enzyme, indicating that this mechanism is not likely to be involved in urate-lowering effects of those compounds. LTE, LTA, lupeol, b-sitosterol, lychnopholide, eremantholide, luteolin and apigenin were also found to inhibit monosodium urate crystals-induced paw oedema in mice. Conclusions: Ethanolic extract of Lychnophora trichocarpha and some of its bioactive compounds may be promising agents for the treatment of gouty arthritis since they possesses both anti-hiperuricemic and anti-inflammatory properties.
Introduction
Gout is a worldwide-distributed inflammatory arthritis, which is caused by the precipitation of monosodium urate crystals (MSU) in the joints (Lioté and Ea, 2006) . Hyperuricemia is kown to be the major risk factor for the development of gout and has also been related to the development of cardiovascular diseases, hypertension, nephrolithiasis and diabetes (Dalbeth and So, 2010; Vá zquez-Mellado et al., 2004) .
In humans, uric acid forms in the final step of purine catabolic pathway, as a product of the oxidation xanthine by the enzyme xanthine oxidoreductase (XDH/XOD). This enzyme exists in two interconvertible forms: xanthine dehydrogenase (XDH) and xanthine oxidase (XOD) (Chung et al., 1997) .
The control of hyperuricemia and the treatment of inflammation are the major therapeutic approaches against gouty arthritis (Liu et al., 2008) . At present, allopurinol is the only drug with clinical application in hyperuricemia that acts by inhibiting XOD activity. Although allopurinol is effective in reducing serum urate levels, it is not an appropriate choice to treat acute gout attacks (Dubchak and Falasca, 2010) . Moreover, this drug has been associated with adverse effects, such as allergic reactions, skin rashes, fever, hepatitis and nephropathy (Dubchak and Falasca, 2010; Haidari et al., 2009 such as indomethacin are often used as first-line therapies for acute inflammation in gout. However, they also present some adverse effects such as gastrointestinal toxicity, renal toxicity, or gastrointestinal bleeding (Sabina et al., 2011) . Therefore, the search for new anti-inflammatory and urate-lowering drugs, including xanthine oxidase inhibitors, which could be useful in gouty arthritis therapy, has motivated a number of recent studies focused on natural products (Ahmad et al., 2008; Haidari et al., 2008 Haidari et al., , 2009 Huang et al., 2011; Liu et al., 2008; Mo et al., 2007; Sabina et al., 2011; Zhu et al., 2004) .
Species of the genus Lychnophora (Asteraceae), popularly known as ''arnicas'', occur only in Brazilian ''cerrado'', in Minas Gerais, Goiá s and Bahia States. Aerial parts of those species are often used in folk medicine to treat pain, bruise, rheumatism, and inflammatory diseases (Cerqueira et al., 1987; Saú de et al., 1998) . Antinociceptive and anti-inflammatory activities of Lychnophora trichocarpha ethanolic extract have been evaluated in previous studies (Guzzo et al., 2008) . This extract was also shown to inhibit XOD activity in vitro (Ferraz-Filha et al., 2006) , although the constituents capable of inhibiting this enzyme have not been identified. Therefore, the aim of this study was to evaluate the in vivo anti-inflammatory, anti-hyperuricemic and liver XOD inhibitory activities of L. trichocarpha and its isolated compounds in mice.
Material and methods

Chemicals and reagents
Xanthine, potassium oxonate, allopurinol, indometacin, luteolin and apigenin were purchased from Sigma-Aldrich. Uric acid assay kit was purchased from Bioclin (Minas Gerais, Brazil). Monosodium urate (MSU) crystals were prepared according to previously described method (Rasool and Varalakshmi, 2006; Sabina et al., 2011) . Sephadex LH-20 (70-100 mm) was purchased from GE Healthcare. Silica gel 60 (40-63 mm or 63-200 mm) was purchased from Merck. Methanol, ethanol, ethyl acetate, hexane dimethylsulphoxide (DMSO) and Tween 80 were of analytical grade.
Plant material
Aerial parts of Lychnophora trichocarpha Spreng. were collected in Minas Gerais, Brazil, in October, 2006. A voucher specimen (20635) is deposited at the herbarium of Instituto de Ciências Exatas e Bioló gicas -UFOP, Ouro Preto, Brazil.
Preparation of plant extract and fractions
Plant material was air-dried and ground. 2.2 kg of the obtained powder was exhaustively extracted with ethanol at room temperature. Solvent was removed under reduced pressure, at 40 1C, 
Isolation and identification of flavonoids
Part of dried LTA (10.0 g) was resuspended with methanol (20 mL) and submitted to partition with hexane (8 Â 30 mL) in order to remove low polarity constituents. The methanol-soluble fraction was chromatographed over a Sephadex LH-20 column (1.5 Â 100 cm) eluted with methanol. Fractions 67-90 (335-450 mL) were combined and chromatographed over silica gel, eluted with CH 2 Cl 2 , ethyl acetate and methanol gradient. Fractions 6-8, eluted with CH 2 Cl 2 : ethyl acetate (70:30), yielded apigenin (4 mg, light yellow solid, mp4300 1C, acetone). Fractions 12-16, eluted with CH 2 Cl 2 : ethyl acetate (50:50 and 40:60), yielded luteolin (10 mg, yellow solid, mp4 300 1C, acetone). Both compounds were identified by NMR spectroscopy and by comparison with spectral literature data (Deng et al., 2004; Ö zgen et al., 2011 ).
Animals
Male albino Swiss mice (25-30 g) were supplied by Universidade Federal de Ouro Preto. Animals were divided into experimental groups (n¼ 6), housed in plastic cages and maintained on a 12-h light/12-h dark cycle. They were given standard chow and water ad libitum. All experimental procedures were approved by the Ethical Committee of Universidade Federal de Ouro Preto, Brazil (no. 2010/58).
2.7. Anti-hyperuricemic effects in oxonate-induced hyperuricemic mice and inhibition of liver XOD activity 2.7.1. Animal model of hyperuricemia in mice An experimental animal model of hyperuricemia induced by potassium oxonate, uricase inhibitor, has been used in order to evaluate the anti-hyperuricemic activity of Lychnophora trichocarpha extract (LTE), ethyl acetate fraction (LTA) and pure compounds, as described elsewhere (Haidari et al., 2008; Hall et al., 1990; Zhu et al., 2004) . Briefly, potassium oxonate (250 mg/kg) dissolved in 0.9% saline solution was administrated intraperitoneally to each animal, except those of normal control group, 1 h before oral administration of test compounds, once a day, for 3 days of the experiment. Mice were anesthetized with ketamine and xylasine (100 and 20 mg/kg, respectively), 1 h after the final drug administration, in order to allow blood collection from abdominal aorta. The blood was allowed to clot for approximately 1 h at room temperature and then centrifuged at 2500 Â g for 10 min. Sera were separated and stored at À 20 1C until assay for uric acid quantification.
Study design and drug administration
LTE, LTA and pure compounds were solubilized in DMSO: Tween:water (1:1:8). Animals were divided into 13 experimental groups (n ¼6). Animals were fasted 2 h before drug administration. Mice of goups 1 and 2 (normal control and hyperuricemic control) received only vehicle by oral route. In group 3 (positive control), animals were treated with allopurinol (10 mg/kg body weight, P.O.). Animals of remaining groups were orally treated with LTE (125 and 250 mg/kg body weight), LTA (62.5 and 125 mg/kg body weight), luteolin, apigenin, eremantholide C, lychnopholide, lupeol or b-sitosterol (25 mg/kg body weight). Treatments were administrated once a day, for three consecutive days.
Uric acid assay
Serum uric acid concentration was determined by enzymaticcolorimetric method, using a standard diagnostic kit (Bioclin, Brazil), according to manufacturer's instructions.
Liver sample preparation
Mice livers were excised immediately after blood collection, washed in 0.9% cold saline and rapidly stored at À 80 1C until further handling. Enzyme extraction has been performed as described elsewhere (Haidari et al., 2008; Zhu et al., 2004) . Briefly, livers were homogenized in 5 mL of 80 mM sodium phosphate buffer (pH 7.4) and, then, the homogenate was centrifuged at 3000 Â g for 10 min at 4 1C. Lipid layer was carefully removed, and supernatant was further centrifuged at 10,000 Â g for 60 min at 4 1C. The final supernatant was used for enzyme assays.
2.7.5. Liver XOD activity assay XOD activity was assayed spectrophotometrically by monitoring uric acid formation from xanthine, according to a previously described method (Hall et al., 1990) , with modification. The reaction mixtures consisted of 50 mM phosphate buffer (pH 7.4), 50 mL liver homogenate, and 1 mM potassium allantoxanate, to avoid oxidation of uric acid to allantoin, in a final volume of 1.65 mL. After preincubation for 15 min at 37 1C, the reaction was initiated by the addition of 350 mL of 250 mM xanthine. The reaction was stopped after 0 and 30 min by adding 0.15 mL of 0.6 M HCl to the reaction medium. Solutions were then centrifuged at 3000 Â g for 5 min. The supernatant were separated and the absorbance measured at 295 nm using a Varian 50Bio UV/VIS spectrophotometer. Protein concentration was determined spectrophotometrically by the method of Bradford (1976) using BSA as standard. XOD activity was expressed as nanomoles of uric acid formed per minute per milligram protein.
2.8. Effects on monosodium urate crystal-induced inflammation in mice 2.8.1. Experimental model of gouty arthritis An experimental model of gouty arthritis was used in order to evaluate the anti-inflammatory activities of LTE, LTA and pure compounds, as described previously (Rasool and Varalakshmi, 2006; Sabina et al., 2008; , with modifications. Monosodium urate (MSU) crystals were suspended in 0.9% sterile saline (40 mg/mL) prior to use. Inflammation was induced, on the first day of the experiment, by intradermal injection of 0.1 mL (4 mg) of MSU suspension into the mice right hind paw. The left paw was injected with vehicle (negative control).
Study design and drug administration
L. trichocarpha extract (LTE), its ethyl acetate fraction (LTA) and pure compounds were solubilized in DMSO: Tween:water (1:1:8). Animals were divided into 12 groups (n ¼6). Treatments were administered 1 h before MSU injection and repeated daily for 2 more days. Mice of goup 1 were orally treated with vehicle and served as MSU-induced control. Mice of group 2 were orally treated with the standard non-steroidal anti-inflammatory drug indometacin (3 mg/kg, P.O.). Animals of remaining groups were orally treated with LTE (125 and 250 mg/kg), LTA (125 and 250 mg/kg), luteolin, apigenin, eremantholide C, lychnopholide, lupeol or b-sitosterol (25 mg/kg).
Paw thickness was measured with a caliper rule (150 mm-6 in, Vonder, China) at 0, 4, 24 and 48 h after MSU injection. Inflammatory swelling was expressed as thickness variation (D).
Statistical analysis
Results of in vivo assays were presented as mean values7S.E.M. Experimental data were analyzed using GraphPad Prism 5.0 Software (Inc., San Diego, CA, U.S.A.). One-way analysis of variance (ANOVA) was used, followed by Student's Newman-Keul's test. P valuesr0.05 were considered statistically significant.
Results
Effects of LTE, LTA and pure compounds on serum urate levels in hyperuricemic mice
Treatment with the uricase inhibitor potassium oxonate significantly increased serum urate levels compared to normal control group. Allopurinol (10 mg/kg), as a positive control, was able to reduce serum urate levels of hyperuricemic mice to values lower than that found in normal animals. A three-day treatment with LTE at the dose of 250 mg/kg, but not at 125 mg/kg, significantly reduced serum urate levels compared to hyperuricemic control group. Fraction LTA showed significant anti-hyperuricemic activity at doses Fig. 1 . Anti-hyperuricemic effects of L. trichocarpha ethanolic extract (LTE), ethyl acetate fraction (LTA) and pure compounds in mice pretreated with potassium oxonate. Experiments were performed as described in Section 2. Data represent mean 7 S.E.M. of 6 animals. One-way ANOVA followed by Student's Newman-Keul's test was used for statistical significance. higher than 62.5 mg/kg. Luteolin, apigenin, lupeol, lychnopholide and eremantholide C were able to significantly reduce serum urate levels at the dose of 25 mg/kg (Fig. 1) .
Effects of LTE, LTA and pure compounds on XOD activity in mice liver
Treatment with LTE at the dose of 250 mg/kg was able to inhibit liver XOD activity by 34.8% when compared to hyperuricemic control group. Apigenin also caused significant inhibition of liver XOD activity at the dose of 25 mg/kg (38.4%). Allopurinol inhibited XOD activity by 85.64% (Table 1) .
Effects of LTE, LTA and pure compounds on monosodium urate crystal-induced inflammation in mice
MSU crystals injection caused a significant increase in paw thickness when compared to negative control (left paw). Paw swelling was found to be reduced in mice treated with LTE and LTA both at 125 and 250 mg/kg (Fig. 2) . Lupeol, b-sitosterol, luteolin, apigenin, eremantholide C and lychnopholide, at 25 mg/kg, were also able to reduce the paw swelling induced by MSU crystals injection. Indometacin (3 mg/kg) has also shown a significant anti-inflammatory activity in this study.
Discussion
The sesquiterpene lactones lychnopholide and eremantholide C, the pentacyclic triterpene lupeol and the steroid b-sitosterol have been isolated from L. trichocarpha in previous studies (Oliveira et al., 1996; Saú de et al., 1998) . In the present study, we have isolated luteolin and apigenin from the active LTA fraction. As far as we know, this is the first report of the occurrence of these flavones in L. trichocarpha.
Anti-inflammatory and anti-hyperuricemic properties are convenient for compounds intended to treat gouty arthritis (Ahmad et al., 2008) , but none of the clinically available medicines has both effects at the same time (Liu et al., 2008) . A previous study (Ferraz-Filha et al., 2006) demonstrated that ethyl acetate and ethanolic extracts of L. trichocarpha inhibit XOD in vitro, showing IC 50 ¼6.2 and 28.8 mg/mL, respectively, which justifies the study of this species in order to identify its active compounds and to evaluate their anti-hyperuricemic effects in vivo. Moreover, L. trichocarpha anti-inflammatory property has been demonstrated in a preliminary screening study (Guzzo et al., 2008) , as suggested by its popular use. Thus, the present study aimed at investigating the effects of this species and its main known constituents in an animal model of gouty arthritis. LTE and LTA have shown dose-dependent anti-hyperuricemic effects on oxonate-pretreated mice in vivo. LTA seemed to be more potent in reducing urate levels than LTE, which, a priori, was consistent with results reported by Ferraz-Filha et al. (2006) regarding the XOD inhibition in vitro. However, LTA was not able to significantly inhibit mice liver XOD activity in vivo at doses up to 125 mg/Kg, which indicates that this fraction may accomplish its anti-hyperuricemic effect mainly through other action mechanisms.
Lychnopholide, eremantholide C, lupeol, apigenin and luteolin are the main responsible for LTA urate-lowering effect. Eremantholide C, lychnopholide, lupeol and luteolin did not shown significant effect towards liver XOD activity. Thus, the uratelowering effects of those compounds are probably due to other mechanisms which must be further investigated. Apigenin, in turn, was able to moderately inhibit liver XOD activity, which was accompanied by a reduction in serum urate levels. Apigenin has been shown to be a potent competitive XOD inhibitor in previous studies (Lin et al., 2002; Van-Hoorn et al., 2002) , showing an IC 50 value of 0.75 mM (Van-Hoorn et al., 2002) . Therefore, this mechanism is likely to contribute for the urate-lowering effects of this compound in vivo.
MSU crystal-induced inflammation is characterized by infiltration of neutrophils and subsequent release of damage-causing oxygen derived free radicals, lysosomal enzymes, as well as prostaglandin E2, leukotrienes and interleukin-1 (Liu et al., 2008; Sabina et al., 2011) . Results of our study suggest that LTE and its fraction LTA can limit MSU-induced acute inflammatory response.
Such activity is probably due to the combined effects of lupeol, bsitosterol, lychnopholide, eremantholide C, luteolin and apigenin.
Previous studies have shown that topical treatment with lupeol or b-sitosterol inhibit neutrophil migration in 12-O-tetradecanoyl-phorbol acetate (TPA) induced ear oedema model (Ferná ndez et al., 2001; Navarro et al., 2001) . Lupeol was also shown to inhibit IL-1, TNF-a and PGE 2 release by macrophages in vitro (Ferná ndez et al., 2001) and to modulate NF-kB transcription factor pathway (Saleem et al., 2004) . Thus, the inhibitory effect of those compounds on MSU-induced paw oedema is probably mediated by the above-mentioned mechanisms. Luteolin and apigenin have been found to modulate COX-2 and iNOS expression and to down regulate the release of NO and TNF-a (Kim et al., 2004; Ló pez-Lá zaro, 2009; Mattace Raso et al., 2001) . Apigenin was shown to inhibit NF-kB expression as well (Kim et al., 2004) . Moreover, these flavones are known to possess strong antioxidant and free radical scavenging properties (Gomes et al., 2008) , and could thus reduce cellular damage caused by superoxide and other reactive oxygen species that are involved in acute inflammation in gout.
Although some sesquiterpene lactones structurally related to lychnopholide and eremantholide C have been shown to inhibit the DNA binding of NF-kB (Rüngeler et al., 1999) , the exact action mechanism by which these two compounds exert their antiinflammatory activity has not been well elucidated so far.
Conclusion
The ethanolic extract of L. trichocarpha (LTE) and its ethyl acetate fraction (LTA) were able to reduce serum urate levels in hyperuricemic mice. Anti-hyperuricemic activities of LTA and LTE are, in part, due to the synergistic actions of the apigenin, luteolin, lupeol, lychnopholide and eremantholide C. The anti-hyperuricemic activity of the apigenin seems to be mediated by XOD inhibition, while eremantholide C, lupeol, luteolin and lychnopholide are likely to possess other action mechanisms. Furthermore, LTE, LTA and its pure constituents proved to be effective in reducing MSU-induced paw oedema in mice. Therefore, L. trichocarpha and some of its active compounds may be promising agents for the treatment of gouty arthritis.
